Novavax Q2 2026 revenue $57M, net loss $53M; raises full-year revenue framework to $235-275M

NOVAVAX INC

2026-Q2 EPS reported -$0.38 revenue$196,212,000

Total revenue $57M (down 76% YoY); net loss $53M vs net income $107M in Q2 2025.
Raised full-year 2026 Adjusted Total Revenue framework to $235-275M (from $230-270M).
Sanofi partnership: Phase 3 CIC trial start triggers $125M milestone; tech transfer completion mid-2027 triggers $75M milestone.
Cash $724M as of June 30, 2026, down from $751M at Dec 31, 2025.
Combined R&D and SG&A expense guidance improved to $370-410M (from $380-420M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.